clinical trial bivalent anew jersey76avictoria75 influenza vaccine highrisk child various dos two wholevirus one splitproduct bivalent influenza anew jersey76avictoria75 vaccine administered 253 child aged six 18 year statistically significant difference either reactivity humoral antibody response among 167 child seven chronic disease category 86 healthy child wholevirus vaccine associated unacceptably high rate reaction given sufficiently antigenic initial dos relatively nonreactive used booster immunization splitproduct vaccine reactive placebo vaccine preparation induced adequate seroconversion rate protective titer antibody avictoria virus one dose anew jersey virus two dos